文献速递糖尿病

PRECISE研究中植入式持续葡萄糖传感器的准确性与使用寿命:一项180天、前瞻性、多中心、关键性试验

Accuracy and Longevity of an Implantable Continuous Glucose Sensor in the PRECISE Study: A 180-Day, Prospective, Multicenter, Pivotal Trial.
PubMed 文献 · Diabetes Care · 2016-11-04

PRECISE研究在71例18岁及以上1型和2型糖尿病患者中评估Eversense植入式持续葡萄糖监测(CGM)传感器180天的表现。主要终点为静脉参考葡萄糖>4.2 mmol/L时的平均绝对相对差(MARD),结果为11.1%(95%CI 10.5, 11.7)。Clarke误差网格分析显示99.2%的样本位于临床可接受的A区和B区,81%的低血糖事件在30分钟内被CGM系统检测到,研究期间未发生器械相关严重不良事件。

要点

  • 静脉参考葡萄糖>4.2 mmol/L时,Eversense植入式CGM的MARD为11.1%(95%CI 10.5, 11.7)。
  • Clarke误差网格分析中99.2%的样本位于临床可接受的A区和B区。
  • 81%的低血糖事件在30分钟内被CGM系统检测到,研究期间无器械相关严重不良事件。

核心结论

  • 结果表明这种新型植入式CGM系统具有安全性和准确性,支持其作为经皮CGM的替代方案。

研究设计与样本

  • 180天、前瞻性、多中心、关键性试验,纳入71例18岁及以上1型和2型糖尿病患者,使用Eversense(Senseonics Inc.)植入式CGM传感器,在家和诊所使用。
  • 通过八次门诊访视评估CGM准确性,主要终点为静脉参考葡萄糖>4.2 mmol/L时的平均绝对相对差(MARD)。
  • 次要终点包括Clarke误差网格分析和报警性能,主要安全性结局为器械相关严重不良事件;试验注册号NCT02154126。

主要发现

  • 针对参考葡萄糖>4.2 mmol/L的MARD值为11.1%(95%CI 10.5, 11.7)。
  • Clarke误差网格分析显示99.2%的样本位于临床可接受的A区和B区。
  • 81%的低血糖事件被CGM系统在30分钟内检测到。
  • 研究期间未发生器械相关严重不良事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: It is known that continuous glucose monitoring (CGM) systems can lower mean glucose compared with episodic self-monitoring of blood glucose. Implantable CGM systems may provide additional benefits. RESEARCH DESIGN AND METHODS: We studied the Eversense (Senseonics Inc.) implantable CGM sensor in 71 participants aged 18 years and older with type 1 and type 2 diabetes in a 180-day multinational, multicenter pivotal trial. Participants used the CGM system at home and in the clinic. CGM accuracy was assessed during eight in-clinic visits with the mean absolute relative difference (MARD) for venous reference glucose values >4.2 mmol/L as the primary end point. Secondary end points included Clarke Error Grid Analysis and alarm performance. The primary safety outcome was device-related serious adverse events. This trial is registered with ClinicalTrials.gov, number NCT02154126. RESULTS: The MARD value against reference glucose values >4.2 mmol/L was 11.1% (95% CI 10.5, 11.7). Clarke Error Grid Analysis showed 99.2% of samples in the clinically acceptable error zones A and B. Eighty-one percent of hypoglycemic events were detected by the CGM system within 30 min. No device-related serious adverse events occurred during the study. CONCLUSIONS: Our results indicate the safety and accuracy of this new type of implantable CGM system and support it as an alternative for transcutaneous CGM.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Kropff J, Choudhary P, Neupane S, et al. Accuracy and Longevity of an Implantable Continuous Glucose Sensor in the PRECISE Study: A 180-Day, Prospective, Multicenter, Pivotal Trial. Diabetes Care. 2016. PMID: 27815290. doi:10.2337/dc16-1525

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。